MINNEAPOLIS--(BUSINESS WIRE)--Celcuity Inc. (Nasdaq: CELC), a functional cellular analysis company that is discovering new cancer subtypes and developing diagnostic tests designed to significantly improve clinical outcomes of cancer patients treated with targeted therapies, today announced that Eric Lindquist joined the company as its Chief Business Officer.
“We are very excited to have Eric join our team and lead Celcuity’s efforts to establish collaborations with pharmaceutical companies and to foster relationships with oncology thought leaders. Eric’s nearly two decades of experience in the companion diagnostic industry brings critical expertise to Celcuity,” said Chairman and Chief Executive Officer, Brian Sullivan. “During his tenure at several leading diagnostic companies, he developed companion diagnostic partnerships with nearly every major pharmaceutical company.”
Prior to joining Celcuity, Mr. Lindquist was the Global Vice President of Oncology and Rare Disease for Natera, Inc. a leading genetic testing diagnostics company. He was responsible for launching their oncology diagnostic product, Signatera, to the pharmaceutical industry and executed more than 30 Signatera related agreements within the first year of its launch. Eric previously served as the Global Vice President of Customer and Companion Diagnostics at Asuragen, a molecular testing company, and as Director, Business Development and Alliances for Companion Diagnostics, at Roche Diagnostics. Early in his career, he was a sales specialist for molecular and companion diagnostics at Abbott Laboratories and a business area leader at Johnson & Johnson’s Veridex division, where he managed co-development partnerships with pharmaceutical and diagnostic companies.
Celcuity Inc. is a cellular analysis company that is discovering new cancer sub-types and developing diagnostic tests designed to significantly improve the clinical outcomes of cancer patients treated with targeted therapies. Celcuity’s proprietary CELx diagnostic platform uses a patient’s living tumor cells to identify the specific abnormal cellular activity driving a patient’s cancer and the targeted therapy that can best treat that patient’s disease. Celcuity is headquartered in Minneapolis, MN. Further information about Celcuity can be found at www.celcuity.com.